Biochip platforms as functional genomics tools for drug discovery.

Improvements in DNA microarray technology have resulted in the generation of data on a scale that, for the first time, permits detailed scrutiny of the human genome. These data provide the foundation for understanding not only the connections between genes and the purpose of genes in the human genome, but also the molecular basis of genetic defects. These advances have the potential to significantly improve healthcare management by improving disease diagnosis and specifically targeting molecular therapy. Herein, the current state of the technology is reviewed, the commercial platforms used by the biopharmaceutical industry are compared and contrasted, and recent efforts in cross-platform data integration are explored.

[1]  Gary Hardiman,et al.  Microarray platforms--comparisons and contrasts. , 2004, Pharmacogenomics.

[2]  Jonathan Knight,et al.  When the chips are down , 2001, Nature.

[3]  R. Lempicki,et al.  Evaluation of gene expression measurements from commercial microarray platforms. , 2003, Nucleic acids research.

[4]  James L. Winkler,et al.  Accessing Genetic Information with High-Density DNA Arrays , 1996, Science.

[5]  Ravi Kothapalli,et al.  Microarray results: how accurate are they? , 2002, BMC Bioinformatics.

[6]  Jiang Li,et al.  Differential gene expression patterns revealed by oligonucleotide versus long cDNA arrays. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  Sangsoo Kim,et al.  Combining multiple microarray studies and modeling interstudy variation , 2003, ISMB.

[8]  D. Nickerson,et al.  Variation is the spice of life , 2001, Nature Genetics.

[9]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[10]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[11]  R. Shippy,et al.  An assessment of Motorola CodeLink microarray performance for gene expression profiling applications. , 2002, Nucleic acids research.

[12]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T. Kennedy.  Managing the drug discovery/development interface , 1997 .

[15]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[16]  T. Barrette,et al.  Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. , 2002, Cancer research.

[17]  M. Reinders,et al.  Genetic network modeling. , 2002, Pharmacogenomics.

[18]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[19]  Z. Szallasi,et al.  Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements. , 2004, Nucleic acids research.

[20]  Karl Kornacker,et al.  Chipping away at the chip bias: RNA degradation in microarray analysis , 2003, Nature Genetics.

[21]  Jaak Vilo,et al.  Regulatory sequence analysis: application to the interpretation of gene expression , 2001, European Neuropsychopharmacology.

[22]  Kristina Hanspers,et al.  Spotted long oligonucleotide arrays for human gene expression analysis. , 2003, Genome research.

[23]  Lucila Ohno-Machado,et al.  Analysis of matched mRNA measurements from two different microarray technologies , 2002, Bioinform..

[24]  W. Wong,et al.  Functional annotation and network reconstruction through cross-platform integration of microarray data , 2005, Nature Biotechnology.

[25]  P. Brown,et al.  Drug target validation and identification of secondary drug target effects using DNA microarrays , 1998, Nature Medicine.

[26]  G. Churchill,et al.  A comparison of cDNA, oligonucleotide, and Affymetrix GeneChip gene expression microarray platforms. , 2004, Journal of biomolecular techniques : JBT.

[27]  Julie A. Johnson.  Drug Target Pharmacogenomics , 2001 .

[28]  Carole L Yauk,et al.  Comprehensive comparison of six microarray technologies. , 2004, Nucleic acids research.

[29]  R G Ulrich,et al.  Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. , 2001, Toxicology letters.

[30]  D. Davison,et al.  d2_cluster: a validated method for clustering EST and full-length cDNAsequences. , 1999, Genome research.

[31]  Yudong D. He,et al.  Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer , 2001, Nature Biotechnology.

[32]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[33]  Richard S Paules,et al.  An overview of toxicogenomics. , 2002, Current issues in molecular biology.

[34]  David Haussler,et al.  Gene structure-based splice variant deconvolution using a microarry platform , 2003, ISMB.